Epizyme’s investors are Kleiner Perkins Caufield & Byers, MPM Capital, Amgen Ventures, Bay City Capital, Astellas Venture Management and New Enterprise Associates, blue-chip venture capital firms who share Epizyme’s vision and commitment to rapidly translating epigenetic understandings of biology into powerful new medicines.